Extracellular microRNA: A new source of biomarkers

Etheridge, Alton; Lee, Inyoul; Hood, Leroy; Galas, David J.; Wang, Kai

doi:10.1016/j.mrfmmm.2011.03.004

Cited by 585 publications

(464 citation statements)

References 72 publications

Supporting

Mentioning

449

Contrasting

Unclassified

Order By: Relevance

“…Previous studies have reported that certain miRNAs may be used as biomarkers for the diagnosis and prognosis of breast cancer and various diseases (25,26). As compared with conventional protein-based biomarkers, certain miRNAs have several potential advantages, including easy detection by PCR, relative homogeneity and highly specific expression profiles (25).…”

Section: Discussionmentioning

confidence: 99%

The combined use of miRNAs and mRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma

Zhao

Liu

Zhong

et al. 2015

International Journal of Molecular Medicine

View full text Add to dashboard Cite

Abstract. Thyroid carcinoma (TC) is the most common malignancy of the endocrine system, and papillary thyroid carcinoma (PTC) accounts for the largest proportion of cases with TC. Although histology is considered the gold standard in the diagnosis of PTC, the sensitivity and specificity of this method is low. Therefore, developing novel diagnostic and prognostic biomarkers for PTC is essential. MicroRNAs (miRNAs or miRs) and their target RNAs play critical roles in tumorigenesis and tumor progression. Thus, the characteristic miRNA and mRNA expression profiles may function as diagnostic biomarkers for tumors, making it possible to predict the tumor stage and the prognosis of patients. In the present study, we detected miRNAs and mRNAs which can function as novel biomarkers for the diagnosis of PTC. The sensitivity of the diagnostic tests was evaluated by receiver operating characteristic curve analysis. Pearson's correlation analysis was used to determine the correlation between mRNAs and miRNAs, and cancer types. We found that the area under the curve (AUC) values of 8 miRNAs (miR-106a, miR-15a, miR-30a, miR-30b, miR-20a, miR-20b, miR-30d and miR-30e) and 8 mRNAs [axis inhibition protein 2 (AXIN2), integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor) (ITGA3), tumor protein p53 inducible nuclear protein (TP53INP)1, TP53INP2, B-cell CLL/lymphoma 2 (BCL2), phosphatase and tensin homolog (PTEN), FOS and K(lysine) acetyltransferase 2B (KAT2B)] were >0.90. The combination of miR-15a and AXIN2 significantly improved the diagnostic accuracy. Therefore, our data indicate that the differential expression of miRNAs combined with that of their target mRNAs may serve as a powerful biomarker for distinguishing PTC from benign tissues.

show abstract

Section: Discussionmentioning

confidence: 99%

The combined use of miRNAs and mRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma

Zhao

Liu

Zhong

et al. 2015

International Journal of Molecular Medicine

View full text Add to dashboard Cite

show abstract

“…19 Therefore, we next measured the levels of circulating tRNA and its derivatives using an anti-m1A antibody-based ELISA. 11 This ELISA assay detects tRNA (unfolded), tRNA-derived fragments (e.g., tiRNA), and mononucleoside free m1A (summarized in Figure 7).…”

Section: The Visualization and Quantification Of Trna Conformational mentioning

confidence: 99%

Conformational Change in Transfer RNA Is an Early Indicator of Acute Cellular Damage

Mishima

Inoue

Saigusa³

et al. 2014

Journal of the American Society of Nephrology

104

View full text Add to dashboard Cite

Tissue damage by oxidative stress is a key pathogenic mechanism in various diseases, including AKI and CKD. Thus, early detection of oxidative tissue damage is important. Using a tRNA-specific modified nucleoside 1-methyladenosine (m1A) antibody, we show that oxidative stress induces a direct conformational change in tRNA structure that promotes subsequent tRNA fragmentation and occurs much earlier than DNA damage. In various models of tissue damage (ischemic reperfusion, toxic injury, and irradiation), the levels of circulating tRNA derivatives increased rapidly. In humans, the levels of circulating tRNA derivatives also increased under conditions of acute renal ischemia, even before levels of other known tissue damage markers increased. Notably, the level of circulating free m1A correlated with mortality in the general population (n=1033) over a mean follow-up of 6.7 years. Compared with healthy controls, patients with CKD had higher levels of circulating free m1A, which were reduced by treatment with pitavastatin (2 mg/d; n=29). Therefore, tRNA damage reflects early oxidative stress damage, and detection of tRNA damage may be a useful tool for identifying organ damage and forming a clinical prognosis.

show abstract

“…The sequences of the majority of miRNAs are conserved among different species and their expression is tissue-or biological stage-specific (20). miRNAs are accessible through non-invasive methods, and can be easily assessed by sensitive and specific methods such as quantitative polymerase chain reaction (qPCR) (19,20).…”

Section: Introductionmentioning

confidence: 99%

Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: A potential blood-based biomarker

Al‐Κafaji

Al‐Mahroos

Al‐Muhtaresh

et al. 2016

Experimental and Therapeutic Medicine

View full text Add to dashboard Cite

Abstract. Circulating microRNAs (miRNAs) have been proposed as promising biomarkers for multiple diseases. miR-126 is reported to be associated with type 2 diabetes mellitus (T2D), diabetic nephropathy (DN) and end stage renal disease. The aim of this study was to investigate the expression of circulating miR-126 and to assess its potential as a blood-based biomarker for DN in T2D patients. In 52 patients with T2D without history of DN (with noromoalbuminuria), 50 patients with T2D and DN (29 with microalbuminuria and 21 with macroalbuminuria), and 50 non-diabetic healthy controls, the expression of circulating miR-126 in peripheral whole blood was evaluated by quantitative polymerase chain reaction. The expression levels of circulating miR-126 were significantly decreased in T2D patients and further decreased in DN patients compared with those in the controls. Multivariate logistic regression analysis confirmed the independent association of lower miR-126 levels with T2D [adjusted odds ratio (OR), 0.797; 95% confidence interval (CI), 0.613-0.960] and DN (adjusted OR, 0.513; 95% CI, 0.371-0.708). miR-126 levels were associated with the degree of albuminuria and showed significantly low expression in DN patients with microalbuminuria (adjusted OR, 0.781; 95% CI; 0.698-0.952) and further lower expression in DN patients with macroalbuminuria (adjusted OR, 0.433; 95% CI, 0.299-0.701), respectively compared with T2D patients with normoalbuminuria. miR-126 levels negatively correlated with albuminuria positively with glomerular filtration rate (P<0.05), and in addition, negatively correlated with fasting glucose, glycated hemoglobin, triglyceride and LDL (P<0.05). Stepwise multiple regression analysis identified albuminuria as a significant predictor of miR-126 (P<0.001). miR-126 in peripheral blood yielded area under the receiver operating characteristic curves of 0.854 (95% CI, 0.779-0.929) and 0.959 (95% CI, 0.916-1.000) in the differentiation of DN patients from T2D patients and DN patients from non-diabetic controls respectively. These data suggest that decreased expression of circulating miR-126 is associated with the development of DN in T2D patients, and may be a promising blood-based biomarker for DN risk estimation.

show abstract

Extracellular microRNA: A new source of biomarkers

Cited by 585 publications

References 72 publications

The combined use of miRNAs and mRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma

The combined use of miRNAs and mRNAs as biomarkers for the diagnosis of papillary thyroid carcinoma

Conformational Change in Transfer RNA Is an Early Indicator of Acute Cellular Damage

Decreased expression of circulating microRNA-126 in patients with type 2 diabetic nephropathy: A potential blood-based biomarker

Contact Info

Product

Resources

About